Clinical and molecular events in patients with Machado-Joseph disease under lamotrigine therapy

Acta Neurologica Scandinavica

Volumn 111, Issue 6, 2005, Pages 385-390

  Liu, C S ^a,b   Hsu, H M ^b   Cheng, W L ^a   Hsieh, M ^c  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c TUNGHAI UNIVERSITY   (Taiwan)

Author keywords

Gait; Lamotrigine; Machado Joseph disease

Indexed keywords

ATAXIN 3; LAMOTRIGINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG HYPERSENSITIVITY; FEMALE; GAIT DISORDER; HEMATOLOGIC DISEASE; HUMAN; LYMPHOBLASTOID CELL; MACHADO JOSEPH DISEASE; MALE; PATIENT POSITIONING; SPINOCEREBELLAR DEGENERATION; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANTICONVULSANTS; CELL LINE, TRANSFORMED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; GAIT ATAXIA; HUMANS; LYMPHOCYTES; MACHADO-JOSEPH DISEASE; MALE; MUSCULOSKELETAL EQUILIBRIUM; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PILOT PROJECTS; REPRESSOR PROTEINS; STEM CELLS; TREATMENT OUTCOME; TRIAZINES;

EID: 18944399907     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2005.00405.x     Document Type: Article

References (34)

1. COUTINHO P, CALHEIROS JM, ANDRADE C. On a new degenerative disorder of the central nervous system, inherited in an autosomal dominant mode and affecting people of Azorean extraction. O Medico 1977;82:446-8.
2. KAWAGUCHI Y, OKAMOTO T, TANIWAKI M et al. CAG expansions in a novel gene from Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994;8:221-7.
3. PAULSON HL, PEREZ MK, TROTTIER Y et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997;19:333-44.
4. ZOGHBI HY, ORR HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000;23:217-47.
5. VAN ALFEN N, SINKE RJ, ZWARTS MJ et al. Intermediate CAG repeat lengths (53, 54) for MJD/SCA3 are associated with an abnormal phenotype. Ann Neurol 2001;49:805-7.
6. YUASA T, OHAMA E, HARAYAMA H et al. Joseph's disease: clinical and pathological studies in a Japanese family. Ann Neurol 1986;19:152-7.
7. MELLO KA, ABBOT BP. Effect of sulfamethoxazole and trimethoprim on neurologic dysfunction in a patient with Joseph's disease. Arch Neurol 1988;45:210-3.
8. SAKAI T, MATSUISHI T, YAMADA S, KOMORI H, IWASHITA H. Sulfamethoxazole-trimethoprim double-blind, placebo-controlled, crossover trial in Machado-Joseph disease: sulfamethoxazole-trimethoprim increases cerebrospinal fluid level of biopterin. J Neural Transm 1995;102:159-72.
9. SAKAI T, ANTOKU Y, MATSUISHI T, IWASHITA H. Tetrahydrobiopterin double-blind, crossover trial in Machado-Joseph disease. J Neurol Sci 1996;136:71-2.
10. SCHULTE T, MATTERN R, BERGER K et al. Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease. Arch Neurol 2001;58:1451-7.
11. TAKEI A, FUKAZAWA T, HAMADA T et al. Effects of tandospirone on '5-HT1A receptor-associated symptoms' in patients with Machado-Joseph disease: an open-label study. Clin Neuropharmacol 2004;27:9-13.
12. MONTE TL, RIEDER CR, TORT AB et al. Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand 2003;107:207-10.
13. KANAI K, KUWABARA S, ARAI K, SUNG JY, OGAWARA K, HATTORI T. Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain 2003;126:965-73.
14. VIOLANTE V, LUONGO A, PEPE I, ANNUNZIATA S, GENTILE V. Transglutaminase-dependent formation of protein aggregates as possible biochemical mechanism for polyglutamine diseases. Brain Res Bull 2001;56:169-72.
15. IENTILE R, CACCAMO D, MACAIONE V, TORRE V, MACAIONE S. NMDA-evoked excitotoxicity increases tissue transglutaminase in cerebellar granule cells. Neuroscience 2002;115:723-9.
16. MESSENHEIMER JA. Lamotrigine. Epilepsia 1995;36(Suppl. 2):S87-94.
17. SCHAPEL GJ, BLACK AB, LAM EL, ROBINSON M, DOLLMAN WB. Combination vigabatrin and lamotrigine therapy for intractable epilepsy. Seizure 1996;5:51-6.
18. HAHN T, FOLDSPANG A, VESTERGAARD E, INGEMANN-HANSEN T. One-leg standing balance and sports activity. Scand J Med Sci Sports 1999;9:15-8.
19. WEN FC, LI YH, TSAI HF et al. Down-regulation of heat shock protein 27 in neuronal cells and non-neuronal cells expressing mutant ataxin-3. FEBS Lett 2003;546:307-14.
20. XIE X, LANCASTER B, PEAKMAN T et al. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain IIA Na+ channels and native Na+ channels in rat hippocampal neurones. Pflugers Arch 1995;430:437-46.
21. WIARD RP, DICKERSON MC, BEEK O, NORTON R, COOPER BR. Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model of global cerebral ischemia. Stroke 1995;26:466-72.
22. CAPUTI L, HAINSWORTH AH, LAVARONI F et al. Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92. Brain Res 2001;919:259-68.
23. CALABRESI P, CENTONZE D, CUPINI LM, COSTA C, PISANI F, BERNARDI G. Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia? Insights from in vitro studies. Neurobiol Dis 2003;12:82-8.
24. MCGEER EG, ZHU SG. Lamotrigine protects against kainate but not ibotenate lesions in rat striatum. Neurosci Lett 1990;112:348-51.
25. SCHULZ JB, MATTHEWS RT, HENSHAW DR, BEAL MF. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 1996;71:1043-8.
26. CONNOP BP, BOEGMAN RJ, BENINGER RJ, JHAMANDAS K. Malonate-induced degeneration of basal forebrain cholinergic neurons: attenuation by lamotrigine, MK-801, and 7-nitroindazole. Neurochemistry 1997;68:1191-9.
27. MAJ R, FARIELLO RG, UKMAR G et al. PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat. Eur J Pharmacol 1998;359:27-32.
28. KREMER B, CLARK CM, ALMQVIST EW et al. Influence of lamotrigine on progression of early Huntington's disease: a randomized clinical trial. Neurology 1999;53:1000-11.
29. GALVAO R, MENDES-SOARES L, CAMARA J, JACO I, CARMOFONSECA M. Triplet repeats, RNA secondary structure and toxic gain-of-function models for pathogenesis. Brain Res Bull 2001;56:191-201.
30. PEEL AL, RAO RV, COTTRELL BA, HAYDEN MR, ELLERBY LM, BREDESEN DE. Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue. Hum Mol Genet 2001;10:1531-8.
31. KETTER TA, MANJI HK, POST RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 2003;23:484-95.
32. TAKEI A, HONMA S, KAWASHIMA A et al. Beneficial effects of tandospirone on ataxia of a patient with Machado-Joseph disease. Psychiatry Clin Neurosci 2002;56:181-5.
33. GAZULLA J, ERREA J, BENAVENTE I, TORDESILLAS C. Improvement of ataxia in cortical cerebellar atrophy with the dog gabapentin. Clin Neuropharmacol 2003;26:225-6.
34. KUZNIECKY R, Ho S, PAN J et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 2002;12:368-72.